At a Glance
- Companies: Litmys, Konovo
- Location: US (Santa Fe, NM)
- Focus area: Drug development intelligence
- Key tech: RAMPx scoring + stakeholder network
- Next steps: Integrated solutions available now
What happened?
Litmys, a life sciences commercial strategy consulting firm, and Konovo, a healthcare intelligence company, announced a partnership on 15 April 2026 to revolutionise drug development intelligence. The collaboration integrates Litmys’ proprietary RAMPx commercial success predictive scoring model with Konovo’s network of over 2 million healthcare stakeholders across the US, Europe and Asia.
Why does it matter?
Life sciences companies face pressure to validate assets earlier amid high R&D failure rates. The partnership enables earlier, smarter decisions on R&D investment and clinical trial design by combining primary insights from HCPs, patients, payers and caregivers with predictive analytics, potentially reducing late-stage surprises, improving portfolio management and strengthening ROI.
Who’s behind it?
Litmys specialises in commercial readiness analytics and Demand Driven Development, headquartered in Santa Fe, New Mexico, with an office in Minneapolis. Konovo provides a technology platform for rapid access to healthcare insights. Harris Kaplan, Litmys Managing Partner, and Tal Rosenberg, Konovo CEO, highlighted the synergy.
How was it achieved?
RAMPx leverages Konovo’s Intelligent Platform for structured qualitative and quantitative assessments from key stakeholders. This predicts product adoption potential early in clinical development, informing endpoints, trial designs and investment choices to maximise future uptake by physicians, payers and patients.
What’s next?
The partnership is effective immediately, offering integrated solutions to life sciences companies and venture capital firms worldwide. Benefits include earlier risk mitigation, reduced time/cost, stronger R&D ROI and comprehensive market intelligence.
What are people saying?
Harris Kaplan, Litmys: “We enable life science companies to focus early development decisions around endpoints and clinical trial designs that drive future uptake.”
Tal Rosenberg, Konovo: “Our collaboration enables partners to connect with the right audiences… to generate insights that drive confident decisions.”